Published in Cochrane Database Syst Rev on January 25, 2005
Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther (2009) 3.47
EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis (2007) 1.90
Prevention of intra-abdominal adhesions using the antiangiogenic COX-2 inhibitor celecoxib. Ann Surg (2006) 0.79
Celecoxib effectively inhibits the formation of joint adhesions. Exp Ther Med (2013) 0.77
The Potential Return on Public Investment in Detecting Adverse Drug Effects. Med Care (2017) 0.75
The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum (1990) 27.50
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med (1999) 20.31
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
A controlled trial of teaching critical appraisal of the clinical literature to medical students. JAMA (1987) 14.20
OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage (2008) 10.99
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials (1995) 9.85
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet (2013) 8.16
OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage (2010) 7.52
Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med (1995) 6.23
A decision aid for women considering hormone therapy after menopause: decision support framework and evaluation. Patient Educ Couns (1998) 5.40
Problems in the handling of clinical and research evidence by medical practitioners. Arch Intern Med (1983) 5.16
Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol (1997) 5.09
A critical appraisal of the efficacy of continuing medical education. JAMA (1984) 4.95
A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) (2003) 4.86
Methodology and reports of systematic reviews and meta-analyses: a comparison of Cochrane reviews with articles published in paper-based journals. JAMA (1998) 4.73
Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group. JAMA (1994) 4.49
Assessing the quality of reports of randomised trials: implications for the conduct of meta-analyses. Health Technol Assess (1999) 4.45
Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol (1993) 4.39
OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence. Osteoarthritis Cartilage (2007) 4.34
Does the inclusion of grey literature influence estimates of intervention effectiveness reported in meta-analyses? Lancet (2000) 4.16
The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol (1998) 3.75
Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med (2001) 3.65
Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 3.65
Rapid bacteriological diagnosis of pyogenic meningitis by latex agglutination. Lancet (1974) 3.64
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 3.45
Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr (1999) 3.45
Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care (1996) 3.37
A randomized trial comparing octylcyanoacrylate tissue adhesive and sutures in the management of lacerations. JAMA (1997) 3.26
The Ottawa patient decision aids. Eff Clin Pract (1999) 3.22
Raised ESR in polymyalgia rheumatica no longer a sine qua non? Lancet (1996) 3.20
Randomized trial of a portable, self-administered decision aid for postmenopausal women considering long-term preventive hormone therapy. Med Decis Making (1998) 3.18
The MACTAR Patient Preference Disability Questionnaire--an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. J Rheumatol (1987) 3.13
Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev (2005) 3.00
The measurement iterative loop: a framework for the critical appraisal of need, benefits and costs of health interventions. J Chronic Dis (1985) 2.96
Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum (2000) 2.92
The effect of elective total hip replacement on health-related quality of life. J Bone Joint Surg Am (1993) 2.85
Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheumatol (1998) 2.77
Pneumococcal antigen in lobar pneumonia. J Clin Pathol (1975) 2.75
Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev (2002) 2.65
Intraarticular corticosteroid for treatment of osteoarthritis of the knee. Cochrane Database Syst Rev (2006) 2.59
ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol (1999) 2.58
Meta-analysis of efficacy of quinine for treatment of nocturnal leg cramps in elderly people. BMJ (1995) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol (1990) 2.50
Multicentre trial to introduce the Ottawa ankle rules for use of radiography in acute ankle injuries. Multicentre Ankle Rule Study Group. BMJ (1995) 2.50
Laboratory evaluation in the diagnosis of Lyme disease. Ann Intern Med (1997) 2.48
Peripheral nerve function in sepsis and multiple organ failure. Chest (1991) 2.46
The International Clinical Epidemiology Network (INCLEN): a progress report. J Clin Epidemiol (1991) 2.32
Dictated versus database-generated discharge summaries: a randomized clinical trial. CMAJ (1999) 2.28
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Contemporary practice patterns in the management of newly diagnosed hypertension. CMAJ (1997) 2.23
Acetaminophen for osteoarthritis. Cochrane Database Syst Rev (2006) 2.21
Setting educational priorities for learning the concepts of population health. Med Educ (1989) 2.19
Warfarin for atrial fibrillation. The patient's perspective. Arch Intern Med (1996) 2.18
Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol (2001) 2.16
Criteria for clinically important changes in outcomes: development, scoring and evaluation of rheumatoid arthritis patient and trial profiles. OMERACT Committee. J Rheumatol (1993) 2.14
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthritis Cartilage (2002) 2.14
Preference for endpoint measures in clinical trials: results of structured workshops. J Rheumatol (1983) 2.13
Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (2002) 2.01
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (2008) 2.00
Preventing perineal trauma during childbirth: a systematic review. Obstet Gynecol (2000) 1.98
Minimal clinically important differences: review of methods. J Rheumatol (2001) 1.94
Tissue adhesive versus suture wound repair at 1 year: randomized clinical trial correlating early, 3-month, and 1-year cosmetic outcome. Ann Emerg Med (1998) 1.93
A comparison of resident performance on real and simulated patients. J Med Educ (1982) 1.92
Knowledge and clinical problem-solving. Med Educ (1985) 1.91
A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage (2002) 1.89
School feeding for improving the physical and psychosocial health of disadvantaged elementary school children. Cochrane Database Syst Rev (2007) 1.88
Do silicone breast implants cause rheumatologic disorders? A systematic review for a court-appointed national science panel. Arthritis Rheum (2001) 1.88
Impact of migraine and tension-type headache on life-style, consulting behaviour, and medication use: a Canadian population survey. Can J Neurol Sci (1993) 1.87
Nature, time course and dose dependence of zidovudine-related side effects: results from the Multicenter Canadian Azidothymidine Trial. AIDS (1989) 1.78
Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol (1996) 1.69
Structure and function of neuronal nicotinic acetylcholine receptors. Prog Brain Res (1996) 1.66
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
A methodological framework to develop and select indices for clinical trials: statistical and judgmental approaches. J Rheumatol (1983) 1.66
Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol (2001) 1.64
Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) (2000) 1.64
Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev (2003) 1.63
Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum (1998) 1.62
Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The Methotrexate-Cyclosporine Combination Study Group. Arthritis Rheum (1997) 1.61
Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis. Osteoporos Int (2000) 1.59
A Canadian survey of transfusion practices in critically ill patients. Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. Crit Care Med (1998) 1.58
Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med (1993) 1.57
Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann Rheum Dis (2007) 1.55
Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett (1995) 1.54
When should hypertension be treated? The different perspectives of Canadian family physicians and patients. CMAJ (2000) 1.51
An hypothesis paper on practice environment and the provision of health care: could hospital occupancy rates effect quality? J Qual Clin Pract (2001) 1.50
Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol (1995) 1.49
The assessment of the economic return from controlled clinical trials. A framework applied to clinical trials of colorectal cancer follow-up. Eur J Health Econ (2003) 1.49